Revenue and Adjusted EBITDA results delivered in line with stated full-year targetsFull‑year cost savings exceeded previously communicated targets Highlights: Revenues of $660.5 million for the fourth quarter and $2,723.4 million for the full yearFourth-quarter book-to-bill ratio of 1.14x, resulting in 1.02x book-to-bill for the trailing 12 monthsGAAP net loss of $(32.5) million, or $(0.35) per diluted share for the fourth quarter; $(986.2) million, or $(10.81) per diluted share for the full yearAdjusted EB ...

Core Viewpoint - ICON Public Limited Company is facing internal scrutiny regarding accounting practices related to revenue recognition, leading to a delay in its financial results for Q4 and full-year 2025 [1][2] Financial Results and Guidance - The company plans to release its delayed financial results on or before April 30, 2026, and has withdrawn its previously issued full-year 2025 financial guidance due to an ongoing investigation by the Audit Committee [2] - Analysts had previously estimated Q4 2025 adjusted EPS to be between $3.27 and $3.32, with revenue expected around $2.00 to $2.01 billion, reflecting modest year-over-year declines [3] - Full-year 2025 consensus estimates for adjusted EPS were in the range of $12.99 to $13.03, with revenue expected between $8.05 and $8.11 billion, down from prior guidance [3] Market Reaction - Following the announcement of the delay and guidance withdrawal, ICON's shares experienced a significant sell-off, dropping approximately 30-40% and reaching multi-year lows in the $70-$90 range [3] Legal Investigations - Multiple law firms have initiated investigations into potential securities law violations, with alerts issued for investors who purchased shares prior to the news [4] Industry Context - ICON operates in the contract research organization (CRO) sector, providing clinical development services to pharmaceutical and biotechnology companies, and competes with firms like IQVIA and Labcorp [4] - The CRO industry relies heavily on accurate revenue recognition for long-term contracts, making the current issues particularly sensitive [4] Financial Metrics - The earnings yield has increased to around 7-8% or higher following the drop in share price, indicating significant uncertainty priced into the market valuation [5] - Trailing P/E ratio is approximately 13-20x, with a price-to-sales ratio around 1.6-1.9x, and enterprise value to sales at approximately 1.3-2.0x [7] - The debt-to-equity ratio stands at 0.38, indicating moderate leverage, while the current ratio is 1.06, suggesting adequate short-term liquidity [7] Future Outlook - The ongoing investigation and delay highlight risks in financial reporting for CROs, with investors awaiting clarity on restated prior periods and updated outlooks for 2025 and 2026 [6]

Charles River Laboratories (NYSE:CRL) Q4 2025 Earnings call February 18, 2026 08:30 AM ET Speaker12I would now like to turn the conference over to your host, Todd Spencer, Vice President of Investor Relations. Please go ahead.Speaker14Good morning, and welcome to Charles River Laboratories' fourth quarter and full year 2025 earnings and 2026 guidance conference call and webcast. This morning, I am joined by Jim Foster, Chair, President, and Chief Executive Officer, Birgit Girshick, Executive Vice President ...

ICON plc Faces Investigation After Internal Probe Reveals Multi-Year Revenue Overstatement [Accessibility Statement] Skip Navigation(NASDAQ: ICLR)NEW YORK, Feb. 18, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP is investigating ICON plc (NASDAQ: ICLR) following the company's disclosure on February 12, 2026, that an internal accounting investigation uncovered preliminary evidence that revenue for fiscal years 2023 and 2024 may have been overstated by up to two percent each year. The disclosure prompted the comp ...

Charles River forecasts upbeat 2026 profit on improved demand for drug development services | ReutersSkip to main content[Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv]- Companies[Charles River Laboratories International Inc]FollowFeb 18 (Reuters) - Contract drug developer Charles River Laboratories [(CRL.N), opens new tab] on Wednesday forecast annual profit above Wall Street estimates, betting on an improvement in demand for its drug discovery and developme ...

此举旨在加强高管团队对早期临床开发的关注，并深化与客户的医疗和科学合作北卡罗来纳州达勒姆, Feb. 18, 2026 (GLOBE NEWSWIRE) -- 全球领先的合同研究组织 (CRO) Fortrea (Nasdaq: FTRE)（以下简称“公司”）今日宣布扩充其高管团队。此前兼任 Fortrea 首席医疗官 (CMO) 和临床药理服务 (CPS) 总裁的 Oren Cohen 医学博士，现专注于其 CMO 职责，主要负责 Fortrea 所有业务的医疗战略、科学领导、伦理和治理监督。Scott Dove 博士加入 Fortrea，担任临床药学服务总裁，负责 Fortrea 在其全球临床研究机构网络中的早期临床开发解决方案。Cohen 和 Dove 均是 Fortrea 的执行委员会成员。 首席执行官 Anshul Thakral 表示：“Scott 加入 Fortrea 团队，同时 Oren 完全专注于开发过程中的医学与科学事务，这对客户而言是一项双赢举措。Oren 将与我们在临床开发各阶段的业务负责人紧密协作，深化其与客户的关系。他更早地参与科学研讨，与公司医师及治疗领域领导者密切协作，共同应对 ...

Adds to executive focus on early clinical development and deepens medical and scientific partnership with clientsDURHAM, N.C., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced it has expanded its executive team. Oren Cohen, MD who previously served as both Fortrea’s chief medical officer (CMO) and president of Clinical Pharmacology Services (CPS) is now dedicated to his CMO responsibilities, namely medical strate ...

The upcoming report from Charles River Laboratories (CRL) is expected to reveal quarterly earnings of $2.33 per share, indicating a decline of 12.4% compared to the year-ago period. Analysts forecast revenues of $985.92 million, representing a decline of 1.7% year over year.The consensus EPS estimate for the quarter has been revised 0.1% higher over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timef ...

Core Viewpoint - ICON Public Limited Company is currently facing an internal investigation into its revenue recognition practices, which has led to a delay in earnings reports and the withdrawal of its 2025 financial guidance [3][4][7]. Group 1: Internal Investigation - The Audit Committee of ICON initiated an internal investigation in late October 2025 regarding certain accounting practices and controls after concerns were raised by company management [5]. - The investigation is being conducted by outside legal counsel with support from forensic and technical accounting firms [5]. - Preliminary findings suggest that ICON's reported revenue for 2023 and 2024 may have been overstated by less than 2% in each fiscal year [6]. Group 2: Financial Impact - Due to the ongoing investigation, ICON has delayed the release of its fourth quarter and full year 2025 earnings results, now expected on or before April 30, 2026 [4]. - The company has withdrawn its previously issued full year 2025 financial guidance and is unable to communicate its 2025 financial performance at this time [7]. - TD Cowen estimates the impact of the investigation on adjusted EPS to be about 13% for 2023 and 12% for 2024 [3]. Group 3: Market Reaction - Following the announcement of the investigation, ICON's share price dropped by 35%, which analysts believe may be an overreaction [3].

Core Viewpoint - Inotiv, Inc. has reported a cybersecurity incident that occurred in early August 2025, involving unauthorized access to its systems and potential acquisition of personal data [1][2][3]. Incident Details - The unusual activity was detected on August 5, 2025, leading to an investigation that confirmed unauthorized actions by a threat actor by August 8, 2025 [3][4]. - The investigation revealed that personal information may have been acquired, including names, Social Security numbers, financial account information, and health-related data [5][6]. Response Actions - Inotiv took immediate steps to contain the incident, launched an investigation with external cybersecurity specialists, and notified regulators and law enforcement [6][7]. - The company has informed affected individuals via mail and email and is offering complimentary credit monitoring services [7][8]. Company Overview - Inotiv, Inc. is a leading contract research organization focused on nonclinical and analytical drug discovery and development services, aiming to enhance efficiency and reduce costs in bringing new drugs and medical devices to market [10][11].